Skip to content
Screener

Net Income at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$100.7M+10.1%
Precigen logo
PrecigenPGEN
-$7.93M+85.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$92M+20.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.88M-34.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$31.5M+18.1%

Segments

By segment

See full
Reportable Segment$78.4M+1,442%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other expense, net(18,991)(23,300)(38,201)(43,769)
Income (loss) before income taxes79,4746,486(641,334)7,244
Income tax expense1,0791,4012,0832,127
Net income (loss)$78,395$5,085$(643,417)$5,117
Other comprehensive (loss) income:
Foreign currency translation adjustment(27)702(89)1,068
Unrealized loss on available for sale investments(133)(188)(477)(343)
Total other comprehensive (loss) income(160)514(566)725

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's net income?
BioCryst Pharmaceuticals (BCRX) reported net income of $78.4M in Q2 2026.
How has BioCryst Pharmaceuticals's net income changed year-over-year?
BioCryst Pharmaceuticals's net income increased by 1441.7% year-over-year, from $5.09M to $78.4M.
What is the long-term trend for BioCryst Pharmaceuticals's net income?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's net income has grown at a 9.4% compound annual growth rate (CAGR), from -$184.06M to $263.86M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about BioCryst Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude